Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Does a Central Venous Line Reduce Perioperative Fluid Administration?

28 de mayo de 2020 actualizado por: Barts & The London NHS Trust

In High Risk Patients Undergoing Elective Colorectal Resection, Does Routine Placement of a Central Venous Catheter Reduce Peri-operative Fluid Administration in Theatre and the Critical Care Unit?

'Hypothesis-generating' study to assess whether the presence of a central venous line significantly affects the volumes of fluid infused perioperatively in major elective colorectal surgery

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

There are several indications for elective central venous cannulation in major colorectal surgery, particularly in those at a higher risk of morbidity and mortality. These include: the ability to infuse certain vasoactive medications, monitor central venous pressure, allow for frequent blood sampling, and provide a route of access for total parenteral nutrition(1). Furthermore, there has been a great deal of recent interest in whether there are improved outcomes with restrictive as opposed to liberal fluid therapy in major abdominal surgery(2), and, similarly, with individualised, rather than generic, blood pressure management in major surgery(3). However, there have been no major studies to date examining whether the simple act of electively inserting a central venous catheter prior to the start of surgery influences the volume of fluid infused and the use of vasopressors perioperatively.

The RELIEF trial reported that modestly liberal perioperative fluid regimens conferred no greater disability-free survival benefit over restrictive regimens, but are likely to reduce rates of acute kidney injury(2). This contrasts with the restrictive protocols championed by various Enhanced Recovery After Surgery (ERAS) programs(4). Previous works have suggested that not only does adherence to ERAS principles lead to superior patient outcomes, but some have gone further in identifying restriction of intravenous fluids perioperatively to be one of the few interventions that independently predicts a better outcome(5). One of the advantages of central venous catheterisation is the ability to administer drugs in smaller volumes of fluid. Therefore, given the intensity of the debate surrounding restrictive and liberal regimens, it should be investigated whether the availability of central venous access impacts upon the volumes of fluid infused.

Furthermore, central venous catheterisation is unlikely just to have an impact via the avoidance of inadvertent larger volume infusion, which is sometimes seen with drug administration through a peripheral line. The RELIEF trial reported that the patient cohort managed with a restrictive fluid regimen were more likely to receive vasopressor support, compared with those receiving a liberal regimen(2). The presence of a central venous catheter enables the use of potent vasopressor agents, such as noradrenaline, which will further influence fluid administration, by introducing a second therapeutic option for correcting perioperative hypotension. The importance of 'tight' blood pressure control has been demonstrated by the INPRESS trial, which showed a reduction in post-operative organ dysfunction with individualised blood pressure management, over standard management strategies(3). This is of particular importance, as evidence has shown that cardiac output-directed fluid therapy should not lead to 'excessive fluid administration, but may lead to a more individualised approach to achieving the correct dose of fluid'(6), and may require concomitant use of vasoactive agents.

Thus, the investigators have set out to investigate whether the elective insertion of a central venous catheter prior to the start of major colorectal surgery, influences the volumes, and types, of fluid infused, as well as the use and mean dose of vasopressor agents, intra-operatively and for the first 12 hours post-operatively.

  1. Smith, RN, et al., 'Central venous catheters', BMJ 2013; 347:f6570
  2. Myles, PS, et al., 'Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery', N Engl J Med 2018; 378:24
  3. Futier, E, et al., 'Effect of Individualised vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery', JAMA 2017; 318(14):1346
  4. Feldheiser, A, et al., 'Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice', Acta Anaesthesiologica Scandinavia 2016, 60:289
  5. Gustafsson, UO, et al., 'Adherence to the Enhanced Recovery After Surgery Protocol and Outcomes After Colorectal Cancer Surgery', Arch Surg 2011; 146(5):571
  6. Pearse, RM, et al., 'Effect of a Perioperative Cardiac Output- Guided Haemodynamic Therapy Algorithm on Outcomes Following Major Gastrointestinal Surgery', JAMA 2014; 311(21):2181

Tipo de estudio

De observación

Inscripción (Actual)

40

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • London, Reino Unido, E11 1NR
        • Whipps Cross Hospital, Barts Health NHS Trust

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adult patients, undergoing elective major colorectal resection, at a district general hospital in east London, UK.

Descripción

Inclusion Criteria:

The inclusion criteria will be all adult patients presenting for elective major colorectal surgery (resection), whom are to be electively admitted to critical care directly from theatre.

Exclusion Criteria:

  • Patients under 18 years of age
  • Patients undergoing emergency surgery
  • Those not admitted electively to critical care directly from theatre
  • Those patients that do not undergo any bowel resection
  • Patients in whom central venous catheter insertion is as an emergency peri- operatively
  • Patients refusing/unable to give valid informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
No CVC inserted
Patients undergoing major elective colorectal resection without central venous catheter inserted pre-operatively
CVC inserted
Patients undergoing major elective colorectal resection with a central venous catheter inserted pre-operatively
Insertion of a central venous catheter insertion pre-operatively (electively)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Volume of intravenous fluid infused intra-operatively
Periodo de tiempo: Intra-operatively (from induction to leaving theatre)
To assess whether the presence of a central venous catheter influences the volume of intravenous fluid infused intra-operatively
Intra-operatively (from induction to leaving theatre)
Volume of intravenous fluid infused post-operatively
Periodo de tiempo: The first 12 hours post-operatively (commencing from the arrival on the critical care unit, until the end of the 12th post-operative hour)
To assess whether the presence of a central venous catheter influences the volume of intravenous fluid infused post-operatively
The first 12 hours post-operatively (commencing from the arrival on the critical care unit, until the end of the 12th post-operative hour)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Length of Intensive Care Unit Stay
Periodo de tiempo: From admission to intensive care, until stepdown to the ward (and until the expected end of study on 30th April 2020)
Does the presence of a central venous catheter alter length of post-operative stay on the Intensive Care Unit
From admission to intensive care, until stepdown to the ward (and until the expected end of study on 30th April 2020)
Volume of blood product infused peri-operatively
Periodo de tiempo: From induction of anaesthesia until the end of the 12th post-operative hour
To assess whether the presence of a central venous catheter influences the volume of blood products infused peri-operatively
From induction of anaesthesia until the end of the 12th post-operative hour
Mean dose of required vasopressor agents
Periodo de tiempo: From induction of anaesthesia until the end of the 12th post-operative hour
To assess whether the presence of a central venous catheter influences the mean dose of any required vasopressor agents peri-operatively
From induction of anaesthesia until the end of the 12th post-operative hour
Use of cardiac output (flow-monitoring) equipment
Periodo de tiempo: From induction of anaesthesia until the end of the 12th post-operative hour
To assess whether the presence of a central venous catheter, and any ensuing fluid and blood pressure management strategies, influence the use of cardiac output monitoring equipment peri-operatively
From induction of anaesthesia until the end of the 12th post-operative hour
Length of hospital stay
Periodo de tiempo: From the day of the procedure until discharge from the hospital (and until the expected end of study on 30th April 2020)
To assess whether the presence of a central venous catheter influences the total post-operative length of stay
From the day of the procedure until discharge from the hospital (and until the expected end of study on 30th April 2020)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: David Melia, MBBS, Barts & The London NHS Trust

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de mayo de 2019

Finalización primaria (Actual)

19 de mayo de 2020

Finalización del estudio (Actual)

19 de mayo de 2020

Fechas de registro del estudio

Enviado por primera vez

7 de junio de 2019

Primero enviado que cumplió con los criterios de control de calidad

12 de junio de 2019

Publicado por primera vez (Actual)

13 de junio de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de mayo de 2020

Última actualización enviada que cumplió con los criterios de control de calidad

28 de mayo de 2020

Última verificación

1 de junio de 2019

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 012593
  • 19/LO/0099 (Otro identificador: HREC)
  • 252375 (Otro identificador: IRAS)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

At this stage there is no plan to make IPD available, and certainly no such intention has been discussed with the relevant ethical and review boards (HREC/HRA).

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir